<DOC>
	<DOC>NCT01009593</DOC>
	<brief_summary>The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.</brief_summary>
	<brief_title>Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)</brief_title>
	<detailed_description>The IDMC recommended discontinuation of the study, and, the protocol was amended to end study treatment.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Neoplasms by Site</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Neoplasms by Histologic Type</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Angiogenesis Modulating Agents</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Inclusion Criteria Histologic or cytologic diagnosis with unresectable or metastatic HCC Child Pugh Class A ECOG performance status 01 Adequate hematologic, hepatic, and renal function Exclusion Criteria Prior systemic (administered intravenously or orally rather than locoregionally) treatment for HCC Prior local therapy (including liverdirected therapy) within 4 weeks from entry Untreated brain or meningeal metastases Current treatment on another clinical trial Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Growth Substances</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>Inhibitors, Angiogenesis</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Growth Inhibitors</keyword>
	<keyword>Angiogenesis Modulating Agents</keyword>
	<keyword>Sorafenib</keyword>
</DOC>